Peter Attia's Peptide Protocol
Peter Attia represents the most cautious and evidence-demanding voice among public figures discussing peptides. As a physician trained in surgical oncology, he evaluates peptides through a rigorous risk-benefit lens and is transparent about the limitations of available evidence. His discussions focus on what the science shows rather than personal experimentation.
Background
Physician focused on the science of longevity and host of The Drive podcast. Dr. Attia is known for his rigorous, evidence-based approach to health optimization and has discussed peptides with notable caution, always contextualizing them against the strength of available evidence.
Peptides Peter Attia Has Discussed
BPC-157
Attia acknowledges the potential of BPC-157 while noting the absence of human clinical trials. His approach is to discuss what the evidence shows rather than advocate for specific protocols.
"Peptides like BPC-157 show a lot of promise for healing and recovery... especially useful for people who experience chronic injuries."
The Drive podcast
Ipamorelin
Discusses GH peptides within a risk-benefit framework, noting the theoretical concerns about IGF-1 elevation and cancer risk with compounds promoting cell growth.
"Growth hormone optimization requires understanding the full context of what we're trying to achieve and what risks we're accepting."
The Drive podcast
Important Considerations
- !Attia prioritizes evidence quality over anecdotal reports
- !His surgical oncology background makes him particularly cautious about growth-promoting compounds
- !He notes the theoretical cancer risk with compounds that promote cell proliferation
- !He emphasizes foundational interventions (exercise, sleep, nutrition) over pharmacological ones
- !His approach may be more conservative than other voices in this space
Frequently Asked Questions
What does Peter Attia think about peptides?
Attia acknowledges that peptides like BPC-157 show promise in preclinical research but emphasizes the lack of human clinical trials. He evaluates them through a risk-benefit framework and is transparent about evidence limitations. His approach is notably more cautious than many other public figures.
Does Peter Attia use peptides?
Attia discusses peptides from a medical evaluation standpoint rather than as a personal advocate. He focuses on what the evidence supports and what questions remain unanswered, consistent with his overall evidence-based approach to longevity medicine.
What is Peter Attia's concern about growth hormone peptides?
As a former surgical oncology fellow, Attia is particularly aware of the theoretical relationship between elevated IGF-1 (stimulated by GH peptides) and cancer risk. He emphasizes understanding the full risk-benefit context before using compounds that promote cell growth and proliferation.